Ezra Cohen, MD

Articles

Dr. Cohen on Future Research Directions in Head and Neck Cancer

April 29th 2021

Ezra Cohen, MD, FRCPSC, FASCO, discusses future research directions for the treatment of patients with head and neck cancer.

Dr. Cohen on the Goals of the SPEARHEAD-2 Trial in Head and Neck Cancer

March 30th 2021

Ezra Cohen, MD, FRCPSC, FASCO, discusses the goals of the phase 2 SPEARHEAD-2 trial in head and neck cancer.

Dr. Cohen on the Design on the SPEARHEAD-2 Trial in Head and Neck Cancer

October 29th 2020

Ezra Cohen, MD, FRCPSC, FASCO, discusses the design of the phase 2 SPEARHEAD-2 trial with ADP-A2M4 plus pembrolizumab in patients with recurrent or metastatic head and neck cancer.

Dr. Cohen on the Era Before Immunotherapy in Head and Neck Cancer

May 29th 2019

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the treatment era before immunotherapy in head and neck cancer.

Dr. Cohen on the Value of PFS as an Endpoint in Head and Neck Cancer

April 5th 2019

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the value of progression-free survival (PFS) as an endpoint in head and neck cancer trials.

Dr. Cohen Discusses Research Questions in Head and Neck Cancer

February 22nd 2019

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses remaining questions regarding the use of immunotherapy in head and neck cancer that still need to be addressed.

Dr. Cohen Discusses Promise of Immunotherapy in Head and Neck Cancer

January 25th 2019

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the promise of immunotherapy in the treatment of patients with head and neck cancer.

Dr. Cohen on Immunotherapeutic Advances in Head and Neck Cancer

October 4th 2018

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapeutic advances in head and neck cancer.

Dr. Cohen on Immunotherapy Combinations in Head and Neck Cancer

December 22nd 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

Dr. Cohen on the Quality of Life in Head and Neck Cancer

November 7th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the unmet need facing the quality of life for patients with head and neck cancer.

Dr. Cohen Discusses Entrectinib in Head and Neck Cancer

October 26th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the role of entrectinib in treating patients with head and neck cancer.

Dr. Cohen Discusses the KEYNOTE-040 Trial in Head and Neck Cancer

September 22nd 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the phase III KEYNOTE-040 trial in head and neck cancer.

Dr. Cohen on Challenges with Immunotherapy in Head and Neck Cancer

August 9th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses challenges with immunotherapy in head and neck cancer.

Dr. Cohen on Immunotherapy in Head and Neck Squamous Cell Carcinoma

July 27th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy in head and neck squamous cell carcinoma.

Dr. Cohen Discusses NK-Directed Therapy in Head and Neck Cancer

July 25th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses natural killer-directed therapy in head and neck cancer.

Dr. Cohen on CAR T-Cell Therapy for Head and Neck Cancer

July 20th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses CAR T-cell therapy for patients with head and neck cancer.

Dr. Cohen Discusses Immunotherapy Combinations in Head and Neck Cancer

July 18th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

Dr. Cohen on Biomarker Testing in Head and Neck Cancer

October 15th 2016

Ezra Cohen, MD, associate director, Moores Cancer Center, professor of Medicine, University of California, San Diego Health System, discusses biomarker testing in patients with head and neck cancer.

Dr. Cohen on Lenvatinib in First- or Second-Line Thyroid Cancer

March 9th 2016

Ezra Cohen, MD, Associate Director, Professor of Medicine Moores Cancer Center, UC San Diego, discusses if lenvatinib should be used in the frontline or second-line setting in differentiated thyroid cancer.

Dr. Cohen on Biomarkers Associated With Response in Patients With HNSCC Treated With Afatinib

February 18th 2016

Ezra Cohen, MD, associate director, Moores Cancer Center, professor of Medicine, University of California, San Diego Health System, discusses tumor biomarker association with clinical outcomes in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with afatinib versus methotrexate.